The estimated Net Worth of Richard James Colonno is at least $2.5 Milhão dollars as of 27 March 2020. Dr Colonno owns over 7,812 units of Assembly Biosciences Inc stock worth over $2,381,216 and over the last 9 years he sold ASMB stock worth over $117,492.
Dr has made over 2 trades of the Assembly Biosciences Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 7,812 units of ASMB stock worth $117,492 on 27 March 2020.
The largest trade he's ever made was exercising 33,061 units of Assembly Biosciences Inc stock on 12 December 2019 worth over $232,419. On average, Dr trades about 4,087 units every 11 days since 2016. As of 27 March 2020 he still owns at least 137,009 units of Assembly Biosciences Inc stock.
You can see the complete history of Dr Colonno stock trades at the bottom of the page.
Dr. Richard J. Colonno is the Sr. Advisor at Assembly Biosciences Inc.
Dr Colonno is 71, he's been the Sr. Advisor of Assembly Biosciences Inc since . There are 3 older and 16 younger executives at Assembly Biosciences Inc. The oldest executive at Assembly Biosciences Inc is Alan Lewis, 74, who is the Independent Director.
Richard's mailing address filed with the SEC is C/O ASSEMBLY BIOSCIENCES, INC., 331 OYSTER POINT BLVD., FOURTH FLOOR, SOUTH SAN FRANCISCO, CA, 94080.
Over the last 10 years, insiders at Assembly Biosciences Inc have traded over $1,523,622 worth of Assembly Biosciences Inc stock and bought 1,245,980 units worth $1,060,065 . The most active insiders traders include Sciences, Inc. Gilead, Myron Z Holubiak, eHelen Susan Kim. On average, Assembly Biosciences Inc executives and independent directors trade stock every 46 days with the average trade being worth of $389,399. The most recent stock trade was executed by Nicole S White on 2 August 2024, trading 785 units of ASMB stock currently worth $11,171.
assembly biosciences, inc. (nasdaq: asmb) is a public clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of hepatitis b virus (hbv) infection and novel oral live biotherapeutics for disorders associated with the microbiome. assembly is developing two innovative platform programs: an hbv program advancing a new class of oral therapeutics for the treatment of hepatitis b virus (hbv) infection and a microbiome program developing novel oral live biotherapeutics designed to address diseases associated with the microbiome. assembly’s hbv program is advancing multiple drug candidates with the aim of increasing cure rates in patients with chronic hbv. the company's microbiome program consists of a fully integrated platform that includes a robust strain identification and selection process, methods for strain isolation and growth under current good manufacturing practices and a patent-pending delivery system, gemicel®, which allows for targeted ora
Assembly Biosciences Inc executives and other stock owners filed with the SEC include: